Nanoparticles are revolutionizing breast cancer diagnosis and treatment through targeted therapy, imaging, and personalized medicine. Their unique physicochemical properties enable efficient drug delivery, enhanced therapeutic efficacy, and reduced systemic toxicity. Applications include improving drug delivery to cancer cells, developing diagnostic tools for early metastasis detection, and integrating with therapies like photothermal therapy and immunotherapy. However, challenges such as chemical feasibility, biodistribution, safety, scalability, and regulatory hurdles remain. Current research highlights the potential of various nanoparticle types, including lipid-based, polymeric, inorganic, and hybrid nanoparticles, in enhancing drug delivery, improving diagnostic accuracy, and enabling theranostic approaches. Nanoparticles offer targeted delivery, passive and active targeting mechanisms, and responsive systems that can release drugs in response to specific tumor conditions. Despite their promise, clinical translation faces obstacles including long-term toxicity, manufacturing challenges, and cost. Future directions focus on overcoming these barriers through multi-omics approaches, combination therapies, and personalized medicine strategies. The integration of nanoparticles into clinical practice holds significant potential for improving breast cancer treatment outcomes through more precise, effective, and less invasive therapies.Nanoparticles are revolutionizing breast cancer diagnosis and treatment through targeted therapy, imaging, and personalized medicine. Their unique physicochemical properties enable efficient drug delivery, enhanced therapeutic efficacy, and reduced systemic toxicity. Applications include improving drug delivery to cancer cells, developing diagnostic tools for early metastasis detection, and integrating with therapies like photothermal therapy and immunotherapy. However, challenges such as chemical feasibility, biodistribution, safety, scalability, and regulatory hurdles remain. Current research highlights the potential of various nanoparticle types, including lipid-based, polymeric, inorganic, and hybrid nanoparticles, in enhancing drug delivery, improving diagnostic accuracy, and enabling theranostic approaches. Nanoparticles offer targeted delivery, passive and active targeting mechanisms, and responsive systems that can release drugs in response to specific tumor conditions. Despite their promise, clinical translation faces obstacles including long-term toxicity, manufacturing challenges, and cost. Future directions focus on overcoming these barriers through multi-omics approaches, combination therapies, and personalized medicine strategies. The integration of nanoparticles into clinical practice holds significant potential for improving breast cancer treatment outcomes through more precise, effective, and less invasive therapies.